Salvat Laboratories announces submission of New Drug Application to the U.S. FDA for Clobetasol Nanoemulsion for treating inflammation and pain after ocular surgery
Salvat Laboratories announced that it has submitted a New Drug Application (NDA) to the FDA for the approval of the first ocular corticosteroid formulated in a nanoemulsion for inflammation and pain in post-ocular surgery patients.
This submission comes after two successful phase III clinical trials conducted between 2020 and 2021. (Source: World Pharma News)
Source: World Pharma News - November 2, 2022 Category: Pharmaceuticals Tags: Featured Business Business and Industry Source Type: news
New TREMFYA ® (guselkumab) Data Show an Overall Clinical Response Rate of Approximately 80 Percent in a Phase 2b Induction Study of Adults with Moderately to Severely Active Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 24, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 2b QUASAR Induction Study 1 in adults with moderately to severely active ulcerative colitis (UC) with inadequate responses to previous treatments. The data presented at the 2022 American College of Gastroenterology (ACG) Annual Scientific Meeting show an overall clinical response rate of approximately 80 percent in patients who were randomized to TREMFYA® (guselkumab).Clinical responsea at weeks 12 or 24 of the study was ultimately achieved by 80.2 percent of patients who w...
Source: Johnson and Johnson - October 24, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
What to Know About Severe Asthma in Kids
Asthma isn’t always a quick and easy diagnosis in children. According to a 2014 task force assembled by the American Thoracic Society and the European Respiratory Society, pediatric severe asthma can be diagnosed if a child’s symptoms require treatment with high-dose inhaled corticosteroids plus a second “controller” medication for a full year, and/or systemic corticosteroids for half a year or longer. In other words, its diagnostic criteria are based on the intractability of its symptoms.
“It’s definitely a limitation when you’re defining a disease state based on how much medicine...
Source: TIME: Health - October 21, 2022 Category: Consumer Health News Authors: Markham Heid Tags: Uncategorized Disease healthscienceclimate Source Type: news
Suffering from Seasonal Allergies? Here ’ s What Experts Say Works Best
Millions of Americans spend weeks each year sneezing and sniffling due to allergies to seasonal triggers such as tree, grass, or ragweed pollen. And for the subset of people who are allergic to year-round household irritants like dust mites, mold, and cockroaches, any season can turn into allergy season.
Allergy symptoms happen when your immune system interprets what should be a relatively benign substance as a threat. The severity of symptoms and the difficulty of treating them can vary depending on your genes, how many substances you’re allergic to, and your level of exposure, says Dr. H. James Wedner, an allergy a...
Source: TIME: Health - October 21, 2022 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized healthscienceclimate medicine Source Type: news
Topical Dermatologic Corticosteroids: In Vivo Bioequivalence
Topical Dermatologic Corticosteroids: In Vivo Bioequivalence (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - October 21, 2022 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Adding Corticosteroid Injection to Exercise Therapy Beneficial in Treating Achilles Tendinopathy
No abstract available (Source: Lippincott's Bone and Joint Newsletter)
Source: Lippincott's Bone and Joint Newsletter - October 20, 2022 Category: Orthopaedics Tags: CME Article Source Type: news
Biologic Dupilumab Shows Sustained Benefit in Asthma Patients
(MedPage Today) -- NASHVILLE, Tenn. -- Treatment with the biologic dupilumab (Dupixent) was associated with sustained reductions in oral corticosteroid (OCS) use in asthma patients who required both low and high daily OCS doses at baseline, according... (Source: MedPage Today Allergy)
Source: MedPage Today Allergy - October 20, 2022 Category: Allergy & Immunology Source Type: news
Johnson & Johnson Reports Q3 2022 Results
New Brunswick, N.J. (October 18, 2022) – Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2022. “Our third quarter performance demonstrates our continued strength and resilience across all three of our businesses,” said Joaquin Duato, Chief Executive Officer. “Through the ongoing efforts of our teams around the world, we continue to navigate the dynamic macroeconomic environment and remain focused on delivering transformative healthcare solutions. Looking ahead, I remain confident in our business and ability to continue advancing our innovative portfolio and pipeline.”OVERALL FINANCIAL ...
Source: Johnson and Johnson - October 18, 2022 Category: Pharmaceuticals Tags: Financial Source Type: news
Early Steroids and VAP in COVID-19-Related ARDS Early Steroids and VAP in COVID-19-Related ARDS
Is early corticosteroid treatment of COVID-19 ARDS associated with a greater risk for developing ventilator-associated pneumonia?Critical Care (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 17, 2022 Category: Consumer Health News Tags: Critical Care Journal Article Source Type: news
STELARA ® (ustekinumab) Demonstrated Sustained Symptomatic and Corticosteroid-Free Remission Through Four Years in Adults with Moderately to Severely Active Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 10, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced final data from the long-term extension (LTE) of the Phase 3 UNIFI study demonstrating efficacy and safety of STELARA® (ustekinumab) through four years of treatment in adult patients with moderately to severely active ulcerative colitis (UC).1 Among all patients who had achieved clinical responsea with STELARA during induction, 64.9 percent were in symptomatic remissionb after 44 weeks of maintenance. At week 200 (four years), this proportion of patients was 55.2 percent; the majority (96.4 percen...
Source: Johnson and Johnson - October 10, 2022 Category: Pharmaceuticals Source Type: news
Results of Novel Clinical Study of Guselkumab and Golimumab Combination Therapy Show Adults with Moderately to Severely Active Ulcerative Colitis Maintained Higher Rates of Clinical, Histologic, and Endoscopic Remission at Week 38
SPRING HOUSE, PENNSYLVANIA, October 10, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from an ongoing analysis of a Phase 2a clinical trial showing adults with moderately to severely active ulcerative colitis (UC) who received 12 weeks of combination induction therapy with guselkumab and golimumab, followed by a transition to guselkumab alone for maintenance, achieved a clinical remission ratea (based on the modified Mayo score [mMayo])b at week 38 of 47.9 percent, a higher rate than induction and maintenance treatment with either guselkumab alone (31.0 percent) or golimumab al...
Source: Johnson and Johnson - October 10, 2022 Category: Pharmaceuticals Source Type: news
Shingles: 'Long-term' use of corticosteroids can trigger reactivation of chickenpox virus
Using a common medication regularly can increase your risk of a shingles flare-up. (Source: Daily Express - Health)
Source: Daily Express - Health - September 25, 2022 Category: Consumer Health News Source Type: news
Research Suggests Adding Corticosteroid Injection and Local Anesthesia to Treatment for Hip Osteoarthritis
No abstract available (Source: Lippincott's Bone and Joint Newsletter)
Source: Lippincott's Bone and Joint Newsletter - September 20, 2022 Category: Orthopaedics Tags: CME Article Source Type: news
Attempted suicide, dexamethasone, and COVID-19: Clinical Case on COVID-19 treatments and the implications for mental health - Plasencia-Garc ía BO, García-Ligero E, Menéndez IE, Gotor F, González-Fuentes Y, Crespo-Facorro B.
The World Health Organization (WHO) declared the outbreak of coronavirus 2019 (COVID-19) a public health emergency on January 30, 2020.1 Corticosteroids (not used in previous epidemics of severe respiratory syndromes due to risk of worsening lung lesion... (Source: SafetyLit)
Source: SafetyLit - September 10, 2022 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news
Biomarker-Guided Steroid Therapy Shown Safe for COPD Biomarker-Guided Steroid Therapy Shown Safe for COPD
Treatment failure rates not significantly lower for eosinophil-guided prescribing of corticosteroids compared with empiric prescribing.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 7, 2022 Category: Consumer Health News Tags: Pulmonary Medicine News Source Type: news
